This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n15http://linked.opendata.cz/ontology/domain/vavai/cep/druhSouteze/
n17http://linked.opendata.cz/ontology/domain/vavai/cep/zivotniCyklusProjektu/
n12http://linked.opendata.cz/ontology/domain/vavai/cep/typPojektu/
dctermshttp://purl.org/dc/terms/
n2http://linked.opendata.cz/resource/domain/vavai/projekt/
n16http://linked.opendata.cz/resource/domain/vavai/subjekt/
n13http://linked.opendata.cz/resource/domain/vavai/cep/prideleniPodpory/
n9http://linked.opendata.cz/ontology/domain/vavai/
n6http://linked.opendata.cz/ontology/domain/vavai/cep/kategorie/
n19http://linked.opendata.cz/ontology/domain/vavai/cep/duvernostUdaju/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n11http://linked.opendata.cz/ontology/domain/vavai/cep/fazeProjektu/
n4http://linked.opendata.cz/ontology/domain/vavai/cep/obor/
n20http://linked.opendata.cz/resource/domain/vavai/projekt/7E13020/
n18http://linked.opendata.cz/ontology/domain/vavai/cep/statusZobrazovaneFaze/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
xsdhhttp://www.w3.org/2001/XMLSchema#
n3http://linked.opendata.cz/ontology/domain/vavai/cep/
n21http://linked.opendata.cz/resource/domain/vavai/cep/vyzva/
n14http://linked.opendata.cz/resource/domain/vavai/aktivita/
n5http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:7E13020
rdf:type
n9:Projekt
rdfs:seeAlso
http://www.isvav.cz/projectDetail.do?rowId=7E13020
dcterms:description
Organ transplantation has emerged as the “gold standard” therapy for end-stage organ failure. Incomplete control of chronic allograft injury but also the adverse effects of long-term immunosuppression (IS) continue to challenge the long-term success of transplantation. The paradigm is shifting from increasing “net”-IS by novel drugs to the concept of minimizing long-term IS as early as possible. However, data were almost completely generated by “trial-and-error” observational studies. It suggests an unmet need to stratify transplant (Tx) patients regarding their immunological responsiveness to the allograft and their respective individual need of IS. The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as “operationally tolerant” by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings–Indices of Tolerance (IOT) and RISET but also of other international groups. Organ transplantation has emerged as the “gold standard” therapy for end-stage organ failure. Incomplete control of chronic allograft injury but also the adverse effects of long-term immunosuppression (IS) continue to challenge the long-term success of transplantation. The paradigm is shifting from increasing “net”-IS by novel drugs to the concept of minimizing long-term IS as early as possible. However, data were almost completely generated by “trial-and-error” observational studies. It suggests an unmet need to stratify transplant (Tx) patients regarding their immunological responsiveness to the allograft and their respective individual need of IS. The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as “operationally tolerant” by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings–Indices of Tolerance (IOT) and RISET but also of other international groups.
dcterms:title
Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation
skos:notation
7E13020
n3:aktivita
n14:7E
n3:celkovaStatniPodpora
n20:celkovaStatniPodpora
n3:celkoveNaklady
n20:celkoveNaklady
n3:datumDodatniDoRIV
2015-04-02+02:00
n3:druhSouteze
n15:RP
n3:duvernostUdaju
n19:S
n3:fazeProjektu
n11:101089222
n3:hlavniObor
n4:FJ
n3:kategorie
n6:AP
n3:klicovaSlova
Organ transplantation; immunosuppression; biomarkers; biomarker-driven strategies; personalizing immunosuppression; investigator-driven biomarker clinical trials; biomarker-based stratification
n3:partnetrHlavni
n16:ico%3A00023001
n3:pocetKoordinujicichPrijemcu
0
n3:pocetPrijemcu
1
n3:pocetSpoluPrijemcu
0
n3:pocetVysledkuRIV
0
n3:pocetZverejnenychVysledkuVRIV
0
n3:posledniUvolneniVMinulemRoce
2014-03-20+01:00
n3:prideleniPodpory
n13:MSMT-42111%2F2013
n3:sberDatUcastniciPoslednihoRoku
n5:2015
n3:sberDatUdajeProjZameru
n5:2015
n3:statusZobrazovaneFaze
n18:DRRVB
n3:typPojektu
n12:P
n3:ukonceniReseni
2017-10-31+01:00
n3:zahajeniReseni
2013-01-01+01:00
n3:zivotniCyklusProjektu
n17:ZBB
n3:vyzva
n21:FP7-HEALTH-2012-INNOVATION-1
n3:klicoveSlovo
Organ transplantation investigator-driven biomarker clinical trials biomarker-driven strategies personalizing immunosuppression immunosuppression biomarkers